Patents by Inventor Fabrice Lejeune

Fabrice Lejeune has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purine derivative for use in the treatment or prevention of diseases caused by a nonsense mutation
    Patent number: 11179398
    Abstract: The present disclosure relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 23, 2021
    Assignees: MUSÉUM NATIONAL D'HISTOIRE NATURELLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ LILLE 1, SCIENCES ET TECHNOLOGIES CITÉ SCIENTIFIQUE
    Inventors: Sylvie Rebuffat, Christine Maulay-Bailly, Séverine Amand, Fabrice Lejeune
  • PURINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES CAUSED BY A NONSENSE MUTATION
    Publication number: 20190240228
    Abstract: The present disclosure relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 8, 2019
    Applicants: MUSÉUM NATIONAL D'HISTOIRE NATURELLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ LILLE 1, SCIENCES ET TECHNOLOGIES
    Inventors: Sylvie Rebuffat, Christine Maulay-Bailly, Séverine Amand, Fabrice Lejeune
  • Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
    Patent number: 10265302
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 23, 2019
    Assignees: UNIVERSITE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLE
    Inventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
  • COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND
    Publication number: 20180147191
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Application
    Filed: January 29, 2018
    Publication date: May 31, 2018
    Inventors: Fabrice LEJEUNE, Benoit DEPREZ, Terence BEGHYN, Sara Sofia GONZALEZ-HILARION
  • Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
    Patent number: 9913829
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLE
    Inventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
  • Compounds derived from indole and pharmaceutical compositions containing them
    Patent number: 8895726
    Abstract: The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or N+R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: November 25, 2014
    Assignees: The Institut Curie, The University of Montpellier 2 Science and Techniques
    Inventors: Fabrice Lejeune, Jamal Tazi, David Grierson, Christian Rivalle, Florence Mahuteau-Betzer
  • COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND
    Publication number: 20130217717
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Application
    Filed: July 29, 2011
    Publication date: August 22, 2013
    Applicants: UNIVERSITE DE DROIT ET SANTE DE LILLE, institut pasteur de lille, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
  • NOVEL COMPOUNDS DERIVED FROM INDOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20110003843
    Abstract: The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or N+R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or
    Type: Application
    Filed: February 19, 2008
    Publication date: January 6, 2011
    Inventors: Fabrice Lejeune, Jamal Tazi, David Grierson, Christian Rivalle, Florence Mahuteau-Betzer